Radioactive technetium phosphate bone scanning in preoperative assessment and follow-up study of patients with primary cancer of the breast.
Seventy-five female patients with early primary cancer of the breast were studied by bone scanning with 99mTc labeled phosphate at the time of initial presentation and serially during follow-up examination. Eleven patients had an abnormal bone scan at the time of presentation. During follow-up periods, which have ranged from three to 34 months with a mean of 16 months, abnormal bone scans have developed in a further 13 patients. To date, nine of the 24 patients with an abnormal bone scan have died, while only one of the 51 with a persistently normal scan has died. It is concluded that an abnormal bone scan carries a significant risk of earlier death due to metastatic disease.
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000175:diagnosis*; D010384:Pelvic Bones / Q000473:pathology; D011183:Postoperative Complications / Q000175:diagnosis; D011300:Preoperative Care; D011877:Radionuclide Imaging; D013667:Technetium
D013667:Technetium